Considerations of delayed gastric emptying with peri-operative use of glucagon-like peptide-1 receptor agonists.

Publisher: Australasian Medical Publishing Co Country of Publication: Australia NLM ID: 0400714 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1326-5377 (Electronic) Linking ISSN: 0025729X NLM ISO Abbreviation: Med J Aust Subsets: MEDLINE

Publication: : Pyrmont, NSW : Australasian Medical Publishing Co.
Original Publication: Sydney : Australasian Medical Pub. Co.

Gastroparesis* ; Diabetes Mellitus, Type 2*/drug therapy; Humans ; Glucagon-Like Peptide-1 Receptor Agonists ; Insulin ; Blood Glucose ; Hypoglycemic Agents

Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016; 375: 1834-1844.
Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375: 311-322.
Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019; 394: 121-130.
Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 2021; 384: 989-1002.
Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med 2021; 385: 503-515.
Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med 2022; 387: 205-216.
Horowitz M, Rayner CK, Marathe CS, Wu T, Jones KL. Glucagon-like peptide-1 receptor agonists and the appropriate measurement of gastric emptying. Diabetes Obes Metab 2020; 22: 2504-2506.
Kuwata H, Yabe D, Murotani K, et al. Effects of glucagon-like peptide-1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: a prospective, observational study. J Diabetes Investig 2021; 12: 2162-2171.
Meier JJ, Rosenstock J, Hincelin-Mery A, et al. Contrasting effects of lixisenatide and liraglutide on postprandial glycemic control, gastric emptying, and safety parameters in patients with type 2 diabetes on optimized insulin glargine with or without metformin: a randomized, open-label trial. Diabetes Care 2015; 38: 1263-1273.
Umapathysivam MM, Lee MY, Jones KL, et al. Comparative effects of prolonged and intermittent stimulation of the glucagon-like peptide 1 receptor on gastric emptying and glycemia. Diabetes 2014; 63: 785-790.
Nauck MA, Kemmeries G, Holst JJ, Meier JJ. Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes 2011; 60: 1561-1565.
Hulst AH, Plummer MP, Hollmann MW, et al. Systematic review of incretin therapy during peri-operative and intensive care. Crit Care 2018; 22: 299.
Hulst AH, Visscher MJ, Godfried MB, et al. Liraglutide for perioperative management of hyperglycaemia in cardiac surgery patients: a multicentre randomized superiority trial. Diabetes Obes Metab 2020; 22: 557-565.
Polderman JAW, van Steen SCJ, Thiel B, et al. Peri-operative management of patients with type-2 diabetes mellitus undergoing non-cardiac surgery using liraglutide, glucose-insulin-potassium infusion or intravenous insulin bolus regimens: a randomised controlled trial. Anaesthesia 2018; 73: 332-339.
Raven LM, Stoita A, Feller RB, et al. Delayed gastric emptying with perioperative use of glucagon-like peptide-1 receptor agonists. Am J Med 2023; https://doi.org/10.1016/j.amjmed.2023.07.016 [Epub ahead of print].
Kobori T, Onishi Y, Yoshida Y, et al. Association of glucagon-like peptide-1 receptor agonist treatment with gastric residue in an esophagogastroduodenoscopy. J Diabetes Investig 2023; 14: 767-773.
Silveira SQ, da Silva LM, de Campos et al. Relationship between perioperative semaglutide use and residual gastric content: a retrospective analysis of patients undergoing elective upper endoscopy. J Clin Anesth 2023; 87: 111091.
Klein SR, Hobai IA. Semaglutide, delayed gastric emptying, and intraoperative pulmonary aspiration: a case report. Can J Anaesth 2023; 70:1394-1396.
Cosson E, Catargi B, Cheisson G, et al. Practical management of diabetes patients before, during and after surgery: a joint French diabetology and anaesthesiology position statement. Diabetes Metab 2018; 44: 200-216.
Hulst AH, Polderman JAW, Siegelaar SE, et al. Preoperative considerations of new long-acting glucagon-like peptide-1 receptor agonists in diabetes mellitus. Br J Anaesth 2021; 126: 567-571.
Joshi GP, Abdelmalak BB, Weigel WA, et al. American Society of Anesthesiologists consensus-based guidance on preoperative management of patients (adults and children) on glucagon-like peptide-1 (GLP-1) receptor agonists. News, 29 June 2023. https://www.asahq.org/about-asa/newsroom/news-releases/2023/06/american-society-of-anesthesiologists-consensus-based-guidance-on-preoperative (viewed Nov 2023).
American Gastroenterological Association. No data to support stopping GLP-1 agonists prior to elective endoscopy. Multi-society statement, 11 Aug 2023. https://gastro.org/news/gi-multi-society-statement-regarding-glp-1-agonists-and-endoscopy/ (viewed Nov 2023).
Willms B, Werner J, Holst JJ, et al. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 1996; 81: 327-332.
Samsom M, Vermeijden JR, Smout AJ, et al. Prevalence of delayed gastric emptying in diabetic patients and relationship to dyspeptic symptoms: a prospective study in unselected diabetic patients. Diabetes Care 2003; 26: 3116-3122.
Parkman HP, Hasler WL, Fisher RS; American Gastroenterological Association. American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. Gastroenterology 2004; 127: 1592-1622.

Keywords: Anesthesia; Diabetes mellitus, type 2; Digestive system abnormalities; Endoscopy; Gastrointestinal hormones

0 (Glucagon-Like Peptide-1 Receptor Agonists)
0 (Insulin)
0 (Blood Glucose)
0 (Hypoglycemic Agents)

Date Created: 20231127 Date Completed: 20240116 Latest Revision: 20240327

20240327

10.5694/mja2.52170

38009941